Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Company Overview

Cognition Therapeutics, Inc. is a clinical‐stage biopharmaceutical company headquartered in Pittsburgh, Pennsylvania, that specializes in developing novel small‐molecule therapies for neurodegenerative diseases. Founded in 2006 as a spin‐out from the University of Pittsburgh, the company has built a proprietary platform targeting synaptic dysfunction and toxic protein aggregates, with a primary focus on Alzheimer’s disease and related dementias. Its research and development team operates from state‐of‐the‐art facilities in the U.S., leveraging both in‐house discovery efforts and strategic academic collaborations to advance its pipeline.

The company’s lead candidate, CT1812, is an oral small‐molecule modulator of the Sigma‐2 receptor complex designed to displace toxic amyloid oligomers from neuronal synapses and restore synaptic function. CT1812 has completed Phase IIa clinical studies in mild‐to‐moderate Alzheimer’s disease, demonstrating favorable safety and target engagement, and is now being evaluated in additional expansion cohorts. In parallel, Cognition Therapeutics is exploring CT1812’s potential in dementia with Lewy bodies and other synaptopathies, as well as advancing next‐generation molecules aimed at improving blood–brain barrier penetration and pharmacokinetic profiles.

Under the leadership of a seasoned management team with decades of combined experience in neuroscience and drug development, Cognition Therapeutics has established partnerships with academic institutions and consortia to support clinical trial execution and biomarker development. The company’s board and scientific advisory panel include experts in neurology, pharmacology, and translational medicine, reflecting its commitment to rigorous science and unmet medical need.

Serving patients and healthcare stakeholders in North America and Europe, Cognition Therapeutics is committed to pioneering treatments that address the underlying mechanisms of neurodegeneration. With a robust intellectual property portfolio and a disciplined approach to clinical advancement, the company aims to deliver first‐in‐class therapeutic options that can alter the course of Alzheimer’s disease and related disorders.

Key Stats

• Today's Range: $0.56 to $0.66
• 50-Day Range: $0.24 to $0.70
• 52-Week Range: $0.22 to $2.54
• Volume: 9.10 million shs
• Average Volume: 4.08 million shs
• Market Capitalization: $35.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.83
• Consensus Rating: Buy

Cognition Therapeutics Stock Analysis - MarketRank™

Cognition Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 427th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cognition Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cognition Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cognition Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.88% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cognition Therapeutics has recently increased by 25.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cognition Therapeutics does not currently pay a dividend.

Dividend Growth

Cognition Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.88% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cognition Therapeutics has recently increased by 25.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.88

News Sentiment

Cognition Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Cognition Therapeutics this week, compared to 2 articles on an average week.

Search Interest

28 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.40% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CGTX Stock Analysis - Frequently Asked Questions

How have CGTX shares performed this year?

Cognition Therapeutics' stock was trading at $0.7013 at the beginning of 2025. Since then, CGTX stock has decreased by 19.1% and is now trading at $0.5674.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.02.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cognition Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGTX
• CIK: 1455365
• Web: www.cogrx.com
• Phone: 412-481-2210
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cognition Therapeutics: $2.83
• High Price Target: $4.00
• Low Price Target: $1.50
• Potential Upside/Downside: +399.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -194.42%
• Return on Assets: -115.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.09
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 61,990,000
• Free Float: 53,066,000
• Market Cap: $35.17 million
• Optionable: Not Optionable
• Beta: 0.88